Clinical Trial Update: SHR-1210 in Recurrent/Metastatic Nasopharyngeal Carcinoma Who Have Received Previous At Least Two Lines of Chemotherapy. [Phase 2]

View source ↗

Summary

Phase 2 trial of SHR-1210 in recurrent/metastatic nasopharyngeal carcinoma after at least two prior lines of chemotherapy has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nasopharyngeal Carcinoma

Drugs mentioned

• SHR-1210 (camrelizumab)

Snippet

Sponsor: Jiangsu HengRui Medicine Co., Ltd. | Conditions: Nasopharyngeal Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2024-03-15